Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareACEPHEN vs VOSOL HC
Comparative Pharmacology

ACEPHEN vs VOSOL HC Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

ACEPHEN vs VOSOL HC

Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.

View ACEPHEN Monograph View VOSOL HC Monograph
ACEPHEN
Non-Opioid Analgesic
Category C
VOSOL HC
Otic Anti-infective with Corticosteroid
Category C
TL;DR — Key Differences
  • Drug class: ACEPHEN is a Non-Opioid Analgesic; VOSOL HC is a Otic Anti-infective with Corticosteroid.
  • Half-life: ACEPHEN has a half-life of Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.; VOSOL HC has Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment..
  • No direct drug-drug interaction has been documented between ACEPHEN and VOSOL HC.
  • Pregnancy: ACEPHEN is rated Category C; VOSOL HC is rated Category C.

Last clinically reviewed: July 2026 · OpiCalc Medical Review Team

Clinical Essentials

ACEPHEN
VOSOL HC
Mechanism of Action
ACEPHEN

ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.

VOSOL HC

Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.

Indications
ACEPHEN

Mild to moderate pain,Fever

VOSOL HC

Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear

Standard Dosing
ACEPHEN

325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.

VOSOL HC

Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.

Direct Interaction
ACEPHEN
No Direct Interaction
VOSOL HC
No Direct Interaction

Pharmacokinetics

ACEPHEN
VOSOL HC
Half-Life
ACEPHEN

Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.

VOSOL HC

Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.

Metabolism
ACEPHEN

Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.

VOSOL HC

Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.

Excretion
ACEPHEN

Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.

VOSOL HC

Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.

Protein Binding
ACEPHEN

Approximately 10-20% bound to serum albumin; extensive tissue binding.

VOSOL HC

90–95%, primarily to albumin.

VD (L/kg)
ACEPHEN

Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.

VOSOL HC

Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.

Bioavailability
ACEPHEN

Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.

VOSOL HC

Otic: 80–90% (local absorption with minimal systemic).

Special Populations

ACEPHEN
VOSOL HC
Renal Adjustments
ACEPHEN

GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.

VOSOL HC

No dosage adjustment required for renal impairment.

Hepatic Adjustments
ACEPHEN

Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.

VOSOL HC

No dosage adjustment required for hepatic impairment.

Pediatric Dosing
ACEPHEN

10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.

VOSOL HC

Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.

Geriatric Dosing
ACEPHEN

Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.

VOSOL HC

No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.

Safety & Monitoring

ACEPHEN
VOSOL HC
Black Box Warnings
ACEPHEN
FDA Black Box Warning

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.

VOSOL HC
FDA Black Box Warning

None

Warnings/Precautions
ACEPHEN

Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.

VOSOL HC

For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane

Contraindications
ACEPHEN

Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.

VOSOL HC

Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy

Adverse Reactions
ACEPHEN
Data Pending
VOSOL HC
Data Pending
Food Interactions
ACEPHEN

Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.

VOSOL HC

No known food interactions. Alcohol consumption is not restricted.

Pregnancy & Lactation

ACEPHEN
VOSOL HC
Teratogenic Risk
ACEPHEN

Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.

VOSOL HC

VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.

Lactation Summary
ACEPHEN

Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).

VOSOL HC

No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.

Pregnancy Dosing
ACEPHEN

No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.

VOSOL HC

No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.

Maternal Safety Status
ACEPHEN
Category C
VOSOL HC
Category C

Clinical Insights

ACEPHEN
VOSOL HC
Clinical Pearls
ACEPHEN

ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.

VOSOL HC

VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.

Patient Counseling
ACEPHEN

Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.

VOSOL HC

Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.

Safety Verification

Known Interactions

ACEPHEN Risks

No interactions on record

VOSOL HC Risks

No interactions on record

Compare Alternatives

Related Drug Comparisons

Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.

ACEPHEN vs INJECTAPAPNon-Opioid Analgesic
VOSOL HC vs INJECTAPAPNon-Opioid Analgesic
ACEPHEN vs OFIRMEVNon-opioid Analgesic
VOSOL HC vs OFIRMEVNon-opioid Analgesic
ACEPHEN vs ACETASOL HCOtic Anti-infective with Corticosteroid
VOSOL HC vs ACETASOL HCOtic Anti-infective with Corticosteroid
Clinical Q&A

Frequently Asked Questions

Common clinical questions about ACEPHEN vs VOSOL HC, answered by our medical review team.

1. What is the main difference between ACEPHEN and VOSOL HC?

ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.

2. Which is stronger: ACEPHEN or VOSOL HC?

Potency comparisons between ACEPHEN and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.

3. What is the standard dosing for ACEPHEN vs VOSOL HC?

The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.

4. Can you take ACEPHEN and VOSOL HC together?

No direct drug-drug interaction has been formally documented between ACEPHEN and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.

5. Are ACEPHEN and VOSOL HC safe during pregnancy?

The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.